Currently, there are 150.38M common shares owned by the public and among those 149.93M shares have been available to trade.
The company’s stock has a 5-day price change of 58.15% and 129.65% over the past three months. MOR shares are trading 74.44% year to date (YTD), with the 12-month market performance up to 230.84% higher. It has a 12-month low price of $3.65 and touched a high of $11.80 over the same period. MOR has an average intraday trading volume of 1.40 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 71.70%, 95.40%, and 129.91% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Morphosys AG ADR (NASDAQ: MOR) shares accounts for 8.10% of the company’s 150.38M shares outstanding.
It has a market capitalization of $2.60B and a beta (3y monthly) value of 1.01. The stock’s trailing 12-month PE ratio is 30.34, while the earnings-per-share (ttm) stands at $0.57. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.48% over the week and 9.79% over the month.
Analysts forecast that Morphosys AG ADR (MOR) will achieve an EPS of $0.09 for the current quarter, -$0.33 for the next quarter and -$1.95 for 2024. The lowest estimate earnings-per-share for the quarter is $0.09 while analysts give the company a high EPS estimate of $0.09. Comparatively, EPS for the current quarter was $2.61 a year ago. Earnings per share for the fiscal year are expected to decrease by -78.69%, and 19.92% over the next financial year.
Looking at the support for the MOR, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on January 16, 2024, with the firm’s price target at $9.20-$10.40.
